Search for a trial

A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney

• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…

Predicited 3D-SAR coverage: a prognostic indicator for treament outcome in superficial hyperthermia for breast cancer recurrences at the chest wall?

The prime objective of the proposed study is to apply treatment modeling for superficial hyperthermia in a well-defined group of patients to investigate the potential of predicted 3-dimensional energy as source for a dose parameter that is…